, Tracking Stock Market Picks
Enter Symbol:

up 1,012.51 %

PHARMASSET INC. (VRUS) rated Buy with price target $34 by Citigroup

Posted on: Tuesday,  Mar 16, 2010  8:25 AM ET by Citigroup

Citigroup rated Buy PHARMASSET INC. (NASDAQ: VRUS) on 03/16/2010, when the stock price was $12.31. Since
then, PHARMASSET INC. has gained 1012.51% as of 01/17/2012's recent price of $136.95.
If you would have followed this Citigroup's recommendation on VRUS, you would have gained 1012.51% of your investment in 672 days.

Pharmasset, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of drugs to treat viral infections. It focuses on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV).

Citi Investment Research is a highly respected research unit and is comprised of 390 research analysts across 22 countries. Citi Investment Research covers 3,100 companies, representing 90 percent of the market capitalization of the major global indices, and provides macro and quantitative analysis of global markets and sector trends. Combined with Citi's exceptional sales and trading capabilities and Smith Barney's financial consultants, the core focus of the group is to help investing clients make informed decisions by providing value-added, independent, insightful analysis.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/16/2010 8:25 AM Buy
12.31 17.00
as of 12/31/2010
1 Week up  10.46 %
1 Month up  12.30 %
3 Months up  65.25 %
1 YTD up  97.60 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy